T he carpometacarpal (CMC) joint is the most common joint in the hand and wrist to undergo surgery. Several different surgical treatments have been proposed, but it remains unclear which approach results in the best outcomes and highest patient satisfaction. One approach is the use of human acellular dermal matrix (HADM) for interposition after trapeziectomy.
RESULTS
Mean preoperative and 1-year follow-up measures are summarized in Table 2 . Study measures improved comparably across both groups. At last follow-up, arthroplasty space was maintained in all patients. There were no complications or adverse reactions associated with the HADM, and no patients required revision in either group.
DISCUSSION
To our knowledge, this is the only prospective study comparing trapeziectomy alone to interposition arthroplasty with HADM. Prior meta-analysis has failed to show definitive proof of the superiority of any particular surgical approach over another for CMC arthritis, 5 and our own study is unable to demonstrate clear superiority of either technique examined. Nonetheless, our findings show HADM interposition to be at least comparable to trapeziectomy, although a major limitation of the study is its small sample size, and therefore, the possibility of type B error cannot be excluded. Cost of the HADM is another limitation to the approach, and further data collection is ongoing to evaluate the durability of both methods over time and to determine whether long-term functionality might justify the initial cost of the allograft. Still, early results suggest that interposition with HADM may offer a safe and effective method of maintaining trapezial height, restoring a functional, painless hand and improving strength while also providing an alternative material to avoid donor-site morbidity or a substitute in revision cases where the surgeon's preferred autograft may already have been used. Ongoing study is warranted to determine the durability of these results over time. 
